<DOC>
	<DOCNO>NCT02798991</DOCNO>
	<brief_summary>The current study design assess safety , tolerability , pharmacokinetics ( PK ) , gastrointestinal ( GI ) transit time pharmacodynamic ( PD ) biomarkers repeat oral dos GSK3179106 administer 14 day normal healthy subject . It randomize , double-blind , placebo-controlled , ascend cohort study . A total 48 subject randomize ( 8 subjects/cohort ) 3:1 allocation GSK3179106 match placebo .</brief_summary>
	<brief_title>A Phase I , Randomized , Placebo-controlled , Double Blind , Repeat Dose Escalation Study Evaluate Safety , Tolerability , Pharmacokinetics , Gastrointestinal Transit Time Pharmacodynamic Biomarkers GSK3179106 Normal Subjects</brief_title>
	<detailed_description />
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Between 18 55 year age inclusive , time signing informed consent . Healthy determine investigator base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . History regular bowel habit Male Female nonchildbearing potential . Capable give sign informed consent include compliance requirement restriction ALT bilirubin &gt; 1.5xupper limit normal ( ULN ) ( isolated bilirubin &gt; 1 . ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Estimated Glomerular Filtration Rate &lt; 60 milliliter per minute per 1.73 square meter ( mL/min/1.73m^2 ) Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) History Gastroesophageal reflux disease ( GERD ) , dyspepsia , GI bleeding , GI surgery could affect motility</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>REarranged Transfection Growth Factor Receptor Tyrosine Kinase Inhibitor</keyword>
</DOC>